Brachytherapy for Inoperable Endometrial Cancer
Author Information
Author(s): Merten Ricarda, Strnad Vratislav, Schweizer Claudia, Lotter Michael, Kreppner Stephan, Fietkau Rainer, Schubert Philipp, Karius Andre
Primary Institution: Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg
Hypothesis
The study aims to evaluate the efficacy and safety of brachytherapy in patients with inoperable endometrial cancer.
Conclusion
Brachytherapy is a safe and effective treatment option for inoperable endometrial cancer, providing good local control and overall survival with minimal toxicity.
Supporting Evidence
- The 5-year overall survival rate was 51%.
- The 5-year disease-free survival rate was 69%.
- 83.3% of patients had their vaginal bleeding stopped.
- No significant difference in disease-free survival was observed in older patients.
- The 5-year cumulative local recurrence rate was 14.9%.
- Patients were treated with either PDR or HDR brachytherapy techniques.
Takeaway
Doctors can use a special type of radiation treatment called brachytherapy to help women with a kind of cancer that can't be treated with surgery, and it works well with few side effects.
Methodology
Eighteen patients with inoperable endometrial cancer were treated with intracavitary brachytherapy between 1990 and 2019, using either PDR or HDR techniques.
Potential Biases
The absence of a randomized control group and incomplete hormone receptor status documentation may introduce bias.
Limitations
The small sample size limits the generalizability of the results and the study's retrospective design lacks a randomized control group.
Participant Demographics
The mean age of participants was 71 years, with significant comorbidities including obesity, diabetes, and hypertension.
Statistical Information
P-Value
0.51
Statistical Significance
p = 0.51
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website